Showing results (151-160 of 212) with videos related to

Sort By:
Pageof 22
European Journal of Cancer (Oxford, England : 1990)|October 12, 2023
Endoscopic and imaging outcomes of PD-1 therapy in localised dMMR colorectal cancerDaniel A Fox, Deepak Bhamidipati, Tsuyoshi Konishi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 8, 2021
ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal CancerAmir Mehrvarz Sarshekeh, Jumanah Alshenaifi, Jason Roszik, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 22, 2008
Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastasesDan G Blazer, Yoji Kishi, Dipen M Maru, et al.
JCO Precision Oncology|July 12, 2021
Comprehensive Clinical and Molecular Characterization of <i>KRAS</i> <sup>G12C</sup>-Mutant Colorectal CancerJason T Henry, Oluwadara Coker, Saikat Chowdhury, et al.
Annals of Surgical Oncology|December 10, 2025
Hepatectomy Plus Chemotherapy or Chemotherapy Alone for Resectable Liver and Unresectable Lung Metastases from Colorectal Adenocarcinoma (LUNA): A Randomized Phase II TrialIan W Folkert, Reza Mehran, Ryan Sun, et al.
Plos One|March 8, 2017
Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancerAmir Mehrvarz Sarshekeh, Shailesh Advani, Michael J Overman, et al.
Science Translational Medicine|August 10, 2022
Adenoviral-based vaccine promotes neoantigen-specific CD8<sup>+</sup> T cell stemness and tumor rejectionAnna Morena D'Alise, Nadia Brasu, Carlo De Intinis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2017
Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal CancerChristine M Parseghian, Nila U Parikh, Ji Yuan Wu, et al.
European Journal of Cancer (Oxford, England : 1990)|July 21, 2025
Prognostic impact of the BRAF V600E mutation in patients with MSI-high metastatic colorectal cancer treated with immune checkpoint inhibitorsClaire Gallois, Margherita Ambrosini, Sara Lonardi, et al.
Cancer Discovery|October 13, 2016
Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E MutationDavid S Hong, Van K Morris, Badi El Osta, et al.
Pageof 22